Variation in nuclear size and PD-L2 positivity correlate with aggressive chromophobe renal cell carcinoma
Language English Country United States Media print-electronic
Document type Journal Article
PubMed
29661724
DOI
10.1016/j.anndiagpath.2018.01.002
PII: S1092-9134(18)30002-9
Knihovny.cz E-resources
- Keywords
- Chromophobe, Nuclear size variation, PD-L2, Prognosis, Renal cell carcinoma,
- MeSH
- Programmed Cell Death 1 Ligand 2 Protein metabolism MeSH
- Cell Nucleus pathology MeSH
- Adult MeSH
- Carcinoma, Renal Cell pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Antibodies, Monoclonal MeSH
- Mice MeSH
- Kidney Neoplasms pathology MeSH
- Prognosis MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Cell Nucleus Size * MeSH
- Animals MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Mice MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Programmed Cell Death 1 Ligand 2 Protein MeSH
- Antibodies, Monoclonal MeSH
- PDCD1LG2 protein, human MeSH Browser
Chromophobe renal cell carcinoma (CRCC) is not amenable to International Society for Urologic Pathology-endorsed nucleolar grading. Novel grading approaches were proposed, but the rarity of adverse pathology hampers their discriminatory value. We investigate simple linear micrometer measurements and a proposed immunostain in CRCCs. 32 patients' CRCCs were studied: 12 adverse cases (stage pT3, recurrence, or metastasis), 15 controls (stage ≤pT2, no recurrence or metastasis after >3 years), and 8 metastases (3 were paired with primary adverse cases). The ratio of greatest dimensions of largest and smallest nuclei, in each of 5 "worst" high-power fields, excluding those with degenerative features, was designated variation in nuclear size (VNS). Percent multinucleate cells (PMC) were also counted. Mouse anti PD-L2 monoclonal antibody immunostaining was performed. Mean VNS measured in adverse primary and control primary tumors were 3.7 ± 0.5 and 2.4 ± 0.4 respectively (P < .001), and 3.4 ± 0.4 for metastases (P < .001). Optimal VNS cut-off was 2.5, with sensitivity and specificity 0.85 and 0.81, respectively. PMCs were 6.0 ± 3.0 for adverse group, 5.7 ± 2.7 for controls, and 4.1 ± 1.6 for metastases (P = NS). PD-L2 could not discriminate adverse versus good primary tumors (χ21.6, P = .2), but was higher in metastases (χ2 6.9, P < .01), or metastases plus adverse primary tumors (χ2 4.8, P = .03), compared to good-pathology primary tumors. In conclusion, VNS is an easily obtained measurement that can predict adverse behavior of chromophobe RCC, and may impart value for needle biopsy reporting and the choice of active surveillance. PD-L2 was elevated in metastases but was less useful for primary tumors.
Department of Biostatistics Medical College of Wisconsin Milwaukee WI United States
Department of Diagnostic Pathology Kochi Red Cross Hospital Japan
Department of Pathology Charles University Faculty of Medicine in Plzeň Czechia
Department of Pathology Instituto Nacional de Cancerologia Mexico D F Mexico
Department of Pathology Medical College of Wisconsin Milwaukee WI United States
References provided by Crossref.org
